Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The closing price of PTC Therapeutics Inc (NASDAQ: PTCT) was $49.76 for the day, up 0.46% from the previous closing price of $49.53. In other words, the price has increased by $0.46 from its previous closing price. On the day, 0.87 million shares were traded. PTCT stock price reached its highest trading level at $50.31 during the session, while it also had its lowest trading level at $49.11.
Ratios:
Our analysis of PTCT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.31 and its Current Ratio is at 2.35.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on March 11, 2025, Upgraded its rating to Neutral and sets its target price to $55 from $41 previously.
On March 07, 2025, Scotiabank started tracking the stock assigning a Sector Perform rating and target price of $55.
Morgan Stanley Upgraded its Equal-Weight to Overweight on December 13, 2024, whereas the target price for the stock was revised from $45 to $67.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 22 ’25 when Klein Matthew B. sold 2,804 shares for $48.74 per share. The transaction valued at 136,656 led to the insider holds 273,234 shares of the business.
Klein Matthew B. bought 2,804 shares of PTCT for $136,656 on Apr 22 ’25. On Apr 02 ’25, another insider, Golden Lee Scott, who serves as the EVP & CHIEF MEDICAL OFFICER of the company, sold 897 shares for $46.95 each. As a result, the insider received 42,114 and left with 75,997 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTCT now has a Market Capitalization of 3924541184 and an Enterprise Value of 5242156544. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.86. Its current Enterprise Value per Revenue stands at 6.498 whereas that against EBITDA is -73.746.
Stock Price History:
The Beta on a monthly basis for PTCT is 0.52, which has changed by 0.547745 over the last 52 weeks, in comparison to a change of 0.097913146 over the same period for the S&P500. Over the past 52 weeks, PTCT has reached a high of $58.38, while it has fallen to a 52-week low of $25.67. The 50-Day Moving Average of the stock is -1.45%, while the 200-Day Moving Average is calculated to be 16.65%.
Shares Statistics:
PTCT traded an average of 937.40K shares per day over the past three months and 941000 shares per day over the past ten days. A total of 77.70M shares are outstanding, with a floating share count of 76.82M. Insiders hold about 2.60% of the company’s shares, while institutions hold 97.51% stake in the company. Shares short for PTCT as of 1744675200 were 5479034 with a Short Ratio of 5.84, compared to 1741910400 on 4302958. Therefore, it implies a Short% of Shares Outstanding of 5479034 and a Short% of Float of 10.6800005.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The company has 2.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $-1.18, with high estimates of $-0.87 and low estimates of $-1.49.
Analysts are recommending an EPS of between $-2.96 and $-4.07 for the fiscal current year, implying an average EPS of $-3.36. EPS for the following year is $-1.83, with 3.0 analysts recommending between $-0.1 and $-2.73.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 10 analysts. It ranges from a high estimate of $1.18B to a low estimate of $149.2M. As of the current estimate, PTC Therapeutics Inc’s year-ago sales were $210.12MFor the next quarter, 10 analysts are estimating revenue of $164.08M. There is a high estimate of $182.27M for the next quarter, whereas the lowest estimate is $145.5M.
A total of 13 analysts have provided revenue estimates for PTCT’s current fiscal year. The highest revenue estimate was $1.75B, while the lowest revenue estimate was $655.6M, resulting in an average revenue estimate of $884.86M. In the same quarter a year ago, actual revenue was $806.78MBased on 13 analysts’ estimates, the company’s revenue will be $844.16M in the next fiscal year. The high estimate is $973.2M and the low estimate is $740M.
